Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes

Hung Yuan Li, Yi Der Jiang, Tien Jyun Chang, Jung Nan Wei, Mao Shin Lin, Cheng Hsin Lin, Fu Tien Chiang, Shyang Rong Shih, Chi Sheng Hung, Cyue Huei Hua, David J. Smith, Jani Vanio, Lee Ming Chuang

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

OBJECTIVE - Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS - The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17-4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17-28.97) for cardiovascular mortality, 6.32 (95% CI 1.25-32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57-65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS - Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors.

Original languageEnglish
Pages (from-to)993-999
Number of pages7
JournalDiabetes
Volume60
Issue number3
DOIs
Publication statusPublished - Mar 2011

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Li, H. Y., Jiang, Y. D., Chang, T. J., Wei, J. N., Lin, M. S., Lin, C. H., Chiang, F. T., Shih, S. R., Hung, C. S., Hua, C. H., Smith, D. J., Vanio, J., & Chuang, L. M. (2011). Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. Diabetes, 60(3), 993-999. https://doi.org/10.2337/db10-0607